PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma

Show other versions (1)

Background: PIM serine/threonine kinases are often highly expressed in haematological malignancies. We have shown that PIM inhibitors reduced the survival and migration of leukaemic cells. Here, we investigated PIM kinases in diffuse large B-cell lymphoma (DLBCL) biopsy samples and DLBCL cell lines....

Bibliografske podrobnosti
Main Authors:	Brault, L, Menter, T, Obermann, E, Knapp, S, Thommen, S, Schwaller, J, Tzankov, A
Format:	Journal article
Izdano:	2012

Podobne knjige/članki

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
od: Brault, L, et al.
Izdano: (2012)

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
od: Brault, L, et al.
Izdano: (2010)

STUDYING THE ROLE OF PIM KINASES IN FLT3-ITD-INDUCED LEUKEMIA REVEALED PIM1 AS REGULATOR OF CXCL12/CXCR4-MEDIATED HOMING AND MIGRATION
od: Brault, L, et al.
Izdano: (2009)

Dissecting Proto-Oncogenic PIM Serine/Threonine Kinases in FLT3-ITD-Induced Leukemogenesis: PIM1 Regulates CXCL12/CXCR4-Mediated Homing and Migration
od: Gasser, C, et al.
Izdano: (2008)

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
od: Grundler, R, et al.
Izdano: (2009)

Structure and substrate specificity of the Pim-1 kinase
od: Bullock, A, et al.
Izdano: (2005)

Structure and substrate specificity of the Pim-1 kinase.
od: Bullock, A, et al.
Izdano: (2005)

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
od: Pogacic, V, et al.
Izdano: (2007)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
od: Bullock, A, et al.
Izdano: (2009)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
od: Akué-Gédu, R, et al.
Izdano: (2009)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1
od: Debreczeni, J, et al.
Izdano: (2006)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1.
od: Debreczeni, J, et al.
Izdano: (2006)

Electrostatically Enhanced Association of a Pim Kinase Substrate Revealed by Stochastic Detection
od: Harrington, L, et al.
Izdano: (2014)

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
od: Bataille, C, et al.
Izdano: (2017)

Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
od: Ekambaram, R, et al.
Izdano: (2013)

Stochastic detection of Pim protein kinases reveals electrostatically enhanced association of a peptide substrate.
od: Harrington, L, et al.
Izdano: (2013)

T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
od: Herbert, K, et al.
Izdano: (2018)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
od: López-Ramos, M, et al.
Izdano: (2010)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
od: López-Ramos, M, et al.
Izdano: (2010)

Effect of single amino acid substitution observed in cancer on Pim-1 kinase thermodynamic stability and structure
od: Lori, C, et al.
Izdano: (2013)

Crystal structure-guided design of bisubstrate inhibitors and photoluminiscent probes for protein kinases of the PIM family
od: Nonga, OE, et al.
Izdano: (2021)

Bromodomains as therapeutic targets.
od: Muller, S, et al.
Izdano: (2011)

Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma.
od: Knapp, S
Izdano: (2013)

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents
od: Da Costa, D, et al.
Izdano: (2010)

Targeting kinases for the treatment of inflammatory diseases.
od: Müller, S, et al.
Izdano: (2010)

Therapeutic interventions for Burkitt lymphoma in children.
od: Okebe, J, et al.
Izdano: (2011)

INTRACELLULAR MARKERS OF DIFFERENTIATION IN BURKITTS-LYMPHOMA
od: Gallagher, C, et al.
Izdano: (1984)

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblas tic Leukaemia (ALL) Cells to DNA Damaging Agents
od: Da Costa, D, et al.
Izdano: (2010)

Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
od: Bullock, A, et al.
Izdano: (2005)

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
od: Miduturu, C, et al.
Izdano: (2011)

Identification of molecular factors mediating therapeutic resistance in diffuse large B-cell lymphoma (DLBCL)
od: Peng, Chenchen
Izdano: (2024)

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
od: Camilleri, E, et al.
Izdano: (2012)

Novel therapeutic approach for cutaneous T-Cell lymphoma
od: Low, Jian Hui
Izdano: (2016)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights (September, pg 3175, 2010)
od: Lopez-Ramos, M, et al.
Izdano: (2011)

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
od: Kizhakeyil, A, et al.
Izdano: (2021)

Recently targeted kinases and their inhibitors-the path to clinical trials.
od: Knapp, S, et al.
Izdano: (2014)

Recently targeted kinases and their inhibitors - the path to clinical trials
od: Knapp, S, et al.
Izdano: (2014)

Emerging intrinsic therapeutic targets for metastatic breast cancer
od: Li, Jiawei, et al.
Izdano: (2023)

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
od: Fedorov, O, et al.
Izdano: (2007)

Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
od: Li, Audrey
Izdano: (2024)